GLG News by Zocor Pricing Experts (US)

Bruce GoldbergPharmacistKOHLL'S PHARMACY & HOMECARE, INC

Rx Savings with Generic vs Branded Medications

March 28, 2011

Analysis of:Buying Brand-Name Drugs Over Generics Raises Medicaid Costs | www.bloomberg.com

With dollar shortfalls for Rx benefits, controlling drug costs is imperative. By utilizing a strict formulary of covered products, along with clear, real time messaging to the pharmacies,  the generic fill rate (GFR) will rise. With a higher GFR, savings is attained.

Bruce GoldbergPharmacistKOHLL'S PHARMACY & HOMECARE, INC

Lupin's opportunity to drop the Lotrel margin!

February 15, 2010

Analysis of:Lupin gets US FDA approval for hypertension capsules | www.pharmabiz.com

The approval of Lupin's generic Lotrel line will create one more player in a field that is currently not very crowded. Yet, don't expect the other players to not react! Generic Lotrel is currently priced relatively high compared to other multi-source hypertensive products.

Bruce GoldbergPharmacistKOHLL'S PHARMACY & HOMECARE, INC

Cetirizine OTC liquid. A day late and a dollar short.

February 8, 2010

Analysis of:Aurobindo Pharma receives final approval for Cetirizine Hydrochloride Solution (OTC) | www.pipelinereview.com

Why the delay? Teva, Taro, and Perrigo all have strong footholds in this market. Rx and OTC competition remains strong, thus what would allow a new player to grow quickly outside of eroding the price market?

Bruce GoldbergPharmacistKOHLL'S PHARMACY & HOMECARE, INC

Reverse Payments for PHRMA smell fishy

May 15, 2008

Analysis of:US trade agency wants to end deals delaying generics | www.reuters.com

Our FTC has gone on record once again stating that the so called "Phrma reverse payments" to generic manufacturers breach antitrust regulations. Delaying competition by simply paying off another supplier, leads to higher prices for me, you, and our families.  My grandpa used to call this stuff by another term....."shmearing".

Dea BelaziPharmacy ConsultantDea Belazi, PharmD, MPH, PAHM

Erythropoiesis Stimulating Agents could be further restricted by Payers (Medicare, PBMs, and Healthplans)

January 28, 2008

Analysis of:FDA Receives New Data on Risks of Anemia Drugs | www.fda.gov

Increased FDA warnings on ESAs, suchas Epogen, Procrit and Aranesp will provide payers the ability to further restrict these agents.   Restrictions will come in the form of prior authorizations and other utilization management techniques.

Dea BelaziPharmacy ConsultantDea Belazi, PharmD, MPH, PAHM

Perhaps the Most Important Reason for Exubera Failure is that No One Wanted to Pay for it

October 29, 2007

Analysis of:Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com

Pfizers failure on Exubera were not of safety issues, or complicated device, or even consumer marketing problems.  Their biggest issue that brought failure was the lack of payer coverage.  Almost no payer in the US added Exubera to their formulary or saw any value over injectable insulin at the price being commanded by Pfizer.

Dea BelaziPharmacy ConsultantDea Belazi, PharmD, MPH, PAHM

WalMart Expansion of $4 generics

October 3, 2007

Analysis of:Wal-Mart Expands Offerings Of $4 Generic Drugs | online.wsj.com

WalMarts strategy on expanding $4 generics is not at a loss.  They are taking a number of generics (in the hunderds) that are nominaly priced and selling them to consumers and still making a profit. 

Dea BelaziPharmacy ConsultantDea Belazi, PharmD, MPH, PAHM

Indian Pharmaceutical Manufacturers

October 3, 2007

Analysis of:Drug discovery hits India | www.icis.com

Indian manufacturers such as Aurabindo, Reddy, Ranbaxy and others are getting on the shelves at the local pharmacies.

Page : 11 to 8 of 8